Genscript Biotech Corporation (HKG:1548)
Hong Kong
· Delayed Price · Currency is HKD 12.68
+0.22 (1.77%)
Mar 28, 2025, 4:08 PM HKT
Genscript Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 594.49 | 839.53 | 625.7 | 490.1 | 390.85 | Upgrade
|
| Revenue Growth (YoY) | -29.19% | 34.17% | 27.67% | 25.39% | 42.98% | Upgrade
|
| Cost of Revenue | 322.36 | 429.98 | 321.62 | 207.58 | 134.95 | Upgrade
|
| Gross Profit | 272.13 | 409.55 | 304.08 | 282.52 | 255.89 | Upgrade
|
| Selling, General & Admin | 202.5 | 387.74 | 350.81 | 302.48 | 197.68 | Upgrade
|
| Research & Development | 53.79 | 432.83 | 390.1 | 358.4 | 263.4 | Upgrade
|
| Operating Expenses | 262.84 | 825.34 | 742.06 | 661.81 | 460.44 | Upgrade
|
| Operating Income | 9.28 | -415.79 | -437.98 | -379.29 | -204.55 | Upgrade
|
| Interest Expense | -8.03 | -27.51 | -13.27 | -2.38 | -1.42 | Upgrade
|
| Interest & Investment Income | 28.89 | 73.19 | 13.22 | 6.55 | 8.01 | Upgrade
|
| Earnings From Equity Investments | -39.07 | - | - | - | -0.6 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.57 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 5.66 | -15.09 | -0.96 | -3.52 | -85.77 | Upgrade
|
| EBT Excluding Unusual Items | -1.71 | -385.2 | -438.98 | -378.63 | -284.33 | Upgrade
|
| Impairment of Goodwill | - | -1.17 | -11.48 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -123.58 | 45.88 | 18.77 | -138.73 | 2.43 | Upgrade
|
| Asset Writedown | -45.51 | -10.49 | - | - | - | Upgrade
|
| Pretax Income | -170.8 | -350.98 | -431.69 | -517.36 | -281.9 | Upgrade
|
| Income Tax Expense | 2.98 | 4.14 | -3.72 | 0.96 | -0.48 | Upgrade
|
| Earnings From Continuing Operations | -173.77 | -355.12 | -427.97 | -518.33 | -281.42 | Upgrade
|
| Earnings From Discontinued Operations | 3,029 | - | - | - | - | Upgrade
|
| Net Income to Company | 2,855 | -355.12 | -427.97 | -518.33 | -281.42 | Upgrade
|
| Minority Interest in Earnings | 106.59 | 259.64 | 201.12 | 159.62 | 76.48 | Upgrade
|
| Net Income | 2,962 | -95.48 | -226.85 | -358.71 | -204.95 | Upgrade
|
| Net Income to Common | 2,962 | -95.48 | -226.85 | -358.71 | -204.95 | Upgrade
|
| Shares Outstanding (Basic) | 2,121 | 2,109 | 2,097 | 2,031 | 1,901 | Upgrade
|
| Shares Outstanding (Diluted) | 2,178 | 2,109 | 2,097 | 2,031 | 1,901 | Upgrade
|
| Shares Change (YoY) | 3.27% | 0.58% | 3.28% | 6.83% | 2.53% | Upgrade
|
| EPS (Basic) | 1.40 | -0.05 | -0.11 | -0.18 | -0.11 | Upgrade
|
| EPS (Diluted) | 1.40 | -0.05 | -0.11 | -0.18 | -0.11 | Upgrade
|
| Free Cash Flow | -121.35 | -539.36 | -336.41 | -269.83 | -272.97 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.26 | -0.16 | -0.13 | -0.14 | Upgrade
|
| Gross Margin | 45.77% | 48.78% | 48.60% | 57.65% | 65.47% | Upgrade
|
| Operating Margin | 1.56% | -49.53% | -70.00% | -77.39% | -52.33% | Upgrade
|
| Profit Margin | 498.22% | -11.37% | -36.26% | -73.19% | -52.44% | Upgrade
|
| Free Cash Flow Margin | -20.41% | -64.24% | -53.76% | -55.06% | -69.84% | Upgrade
|
| EBITDA | 70.43 | -358.52 | -388.9 | -341.57 | -174.71 | Upgrade
|
| EBITDA Margin | 11.85% | -42.70% | -62.15% | -69.69% | -44.70% | Upgrade
|
| D&A For EBITDA | 61.15 | 57.27 | 49.08 | 37.72 | 29.84 | Upgrade
|
| EBIT | 9.28 | -415.79 | -437.98 | -379.29 | -204.55 | Upgrade
|
| EBIT Margin | 1.56% | -49.53% | -70.00% | -77.39% | -52.33% | Upgrade
|
Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.